Logo

Celltrion Receives IND Approval for P-III Trial of CT-P47 (biosimilar, tocilizumab) to Treat Rheumatoid Arthritis in Poland

Share this
Celltrion Receives IND Approval for P-III Trial of CT-P47 (biosimilar, tocilizumab) to Treat Rheumatoid Arthritis in Poland

Celltrion Receives IND Approval for P-III Trial of CT-P47 (biosimilar, tocilizumab) to Treat Rheumatoid Arthritis in Poland

Shots:

  • URPL has approved the IND application of CT-P47 (biosimilar, tocilizumab) to initiate the P-III trial in 448 patients with RA in Poland
  • The company is planning to conduct comparative studies on the efficacy, safety, PK & immunogenicity of CT-P47 vs Acterma through the upcoming trials
  • Actemra is an interleukin formulation that decreases inflammation by blocking the interleukin-6 protein that is responsible for producing inflammation in the body & is used to treat RA, SJIA, polyarticular JIA, GCA & CRS. Additionally, the company is expected to receive the US FDA’s approval for its Humira biosimilar Yuflyma in 2022

Ref:  Korea Biomedical Review | Image: Celltrion

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions